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Abstract
Background:  Bordetella pertussis, the causative agent of whooping cough, is a highly clonal
pathogen of the respiratory tract. Its lack of genetic diversity, relative to many bacterial pathogens,
could limit its ability to adapt to a hostile and changing host environment. This limitation might be
overcome by phase variation, as observed for other mucosal pathogens. One of the most common
mechanisms of phase variation is reversible expansion or contraction of homopolymeric tracts
(HPTs).
Results: The genomes of B. pertussis and the two closely related species, B. bronchiseptica and B.
parapertussis, were screened for homopolymeric tracts longer than expected on the basis of
chance, given their nucleotide compositions. Sixty-nine such HPTs were found in total among the
three genomes, 74% of which were polymorphic among the three species. Nine HPTs were
genotyped in a collection of 90 geographically and temporally diverse B. pertussis strains using the
polymerase chain reaction/ligase detection reaction (PCR/LDR) assay. Six HPTs were polymorphic
in this collection of B. pertussis strains. Of note, one of these polymorphic HPTs was found in the
fimX promoter, where a single base insertion variant was present in seven strains, all of which were
isolated prior to introduction of the pertussis vaccine. Transcript abundance of fimX was found to
be 3.8-fold lower in strains carrying the longer allele. HPTs in three other genes, tcfA, bapC, and
BP3651, varied widely in composition across the strain collection and displayed allelic
polymorphism within single cultures.
Conclusion: Allelic polymorphism at homopolymeric tracts is common within the B. pertussis
genome. Phase variability may be an important mechanism in B. pertussis for evasion of the immune
system and adaptation to different niches in the human host. High sensitivity and specificity make
the PCR/LDR assay a powerful tool for investigating allelic variation at HPTs. Using this method,
allelic diversity and phase variation were demonstrated at several B. pertussis loci.
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Background
Bordetella pertussis causes whooping cough, a highly com-
municable disease that killed roughly 279,000 people and
infected 17.6 million people globally in a recent typical
year [1]. B. pertussis and the closely related human- and
sheep-adapted species, B. parapertussis, have diverged
independently by genome decay from a putative common
ancestor that they share with B. bronchiseptica, which has a
broader host range, and unlike the other two species,
causes chronic infections [2-4]. Re-emergence of pertussis
in certain vaccinated populations [5,6] suggests that B.
pertussis may be adapting to vaccine-induced host immu-
nity [5]. In support of this hypothesis, shifts in the allelic
frequencies of genes encoding at least three vaccine com-
ponents (pertussis toxin, pertactin, and fimbriae) have
been documented in B. pertussis from Finland, Sweden,
France and the Netherlands [5,7-9]. However, multilocus
enzyme electrophoresis (MLEE) [10], comparative
genome hybridization (CGH) [11] and multilocus
sequence typing (MLST) of seven housekeeping genes [4]
have established that B. pertussis is highly clonal with
nearly invariant genome content. The apparent scarcity of
variation in the B. pertussis genome is unusual among bac-
terial pathogens, in which extensive genomic plasticity is
thought to contribute to host immune evasion [12].
Phase variation is one means by which B. pertussis might
adapt to host immune surveillance and vaccine-induced
immune responses without loss or acquisition of genomic
fragments [13]. In a number of pathogenic bacteria, phase
variation influences expression of virulence phenotypes
and creates phenotypic diversity in clonal populations
(reviewed in [14,15]). Phase variation can also influence
the affinity of pathogens for different host anatomical
niches. For example, variable expression of colony opacity
(Opa) proteins changes the tropism of Neisseria  for
human epithelium, endothelium, and phagocytic cells
[16].
The genetic mechanism of phase variation in many cases
is expansion and contraction of nucleotide repeat
sequences (reviewed in [17,18]). Homopolymeric nucle-
otide tracts (HPTs) frequently grow or shrink, with longer
HPTs more prone to slippage. By searching bacterial
genome sequences for unusually long HPTs, putative
phase-variable genes have been identified, and in some
cases, validated [19-22].
B. pertussis undergoes variation between virulent and avir-
ulent phases [23]. The molecular mechanism of this phe-
notypic switch is expansion and contraction of an HPT in
bvgS [24], which encodes a key regulator of virulence gene
expression (reviewed in [25]). In addition, phase-variable
expression of two fimbrial major subunit genes, fim2 and
fim3, has been attributed to variations in HPTs located
within the promoter regions of these genes that lead to
altered transcript abundance [26,27]. In this study, we
sought to identify additional B. pertussis candidate phase-
variable genes, particularly those with potential roles in
pathogenesis. Furthermore, we sought to test whether
these genes were polymorphic in the B. pertussis popula-
tion and, specifically, whether they were phase-variable
over the short time period that characterizes an infectious
cycle.
In order to measure HPT tract length in a rapid, sensitive,
and accurate manner in a large collection of B. pertussis
strains, the polymerase chain reaction/ligase detection
reaction (PCR/LDR) was employed. This assay has been
used to study genomic repeat instability in human tumors
[28] and has been applied to the identification of
rifampin-resistant Mycobacterium tuberculosis strains [29].
The ability of PCR/LDR to identify rare genotypic variants
in a population, and its high fidelity, make this method
well suited for detection of HPT-associated phase varia-
tion events. Using this method, HPT length polymor-
phisms were demonstrated at six out of nine putative
phase-variable loci, among a collection of 90 B. pertussis
isolates. Two of these loci, both encoding Bvg-activated
surface proteins, were found to exhibit rapid and reversi-
ble mutations. Phase variation in B. pertussis is more com-
mon than previously recognized and may be a significant
source of phenotypic diversity in this pathogen.
Results
Validation of PCR/LDR for detection of HPT alleles in 
bacterial genomes
Variation between virulent and avirulent phenotypic
phases in B. pertussis has been attributed to a polymor-
phism within an HPT located in the coding region of the
virulence regulatory sensor kinase gene, bvgS [24]. Viru-
lent strains (e.g., BP370) have 6 cytosines (C6) in this HPT
and produce full-length BvgS. The HPT of avirulent deriv-
ative strains (e.g., BP369) has 7 cytosines (C7), leading to
a translational frameshift that truncates BvgS, rendering it
non-functional [24].
In order to test the utility of PCR/LDR for detecting HPT
polymorphisms, oligonucleotides were designed for dis-
crimination of the C6 and C7 alleles of bvgS (Figure 1A). A
bvgS fragment containing the HPT was amplified by PCR
using a high-fidelity, thermostable DNA polymerase (Pfu
Ultra). Each LDR reaction contained the amplified tem-
plate DNA, thermostable Taq DNA ligase, a 5-carboxyflu-
orescein (FAM)-labeled "common" oligonucleotide, and
one or more unlabeled "discriminating" oligonucleotides
that differ in length from each other by at least three
nucleotides so as to enhance electrophoretic separation of
the ligation products. The common oligonucleotide was
designed to be complementary to 3 bases of the HPT plusBMC Genomics 2007, 8:122 http://www.biomedcentral.com/1471-2164/8/122
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15 bases of downstream sequence. Both the C6 and C7 dis-
criminating oligonucleotides were complementary to 14
bases of the upstream flanking sequence, but they differed
in the number of repeated bases at the 3' end: the C6 dis-
criminating oligonucleotide had three repeated bases, and
the C7 discriminating oligonucleotide had four. When the
sum of the repeated bases at the 3' end of the discriminat-
ing oligonucleotide and the 5' end of the common oligo-
nucleotide equals the number of repeated bases in the
template HPT, the alignment of the oligos on the template
favors the formation of a single-stranded ligation product
with diagnostic size (Figure 1A).
As expected, PCR/LDR analysis of the virulent BP370
strain with the C6 discriminating oligonucleotide yielded
an abundant ligation product (Figure 1B). However, PCR/
LDR with the C7 discriminating oligonucleotide prepara-
tion also produced a ligation product, albeit more faint.
This finding can be attributed to oligonucleotide synthesis
errors (see capillary electrophoresis data in Additional file
1) that cause a fraction of the oligonucleotides (denoted
"C7-1") in the HPLC-purified synthesis product to contain
one fewer cytosine at the 3' end. These rare synthesis arti-
facts can, in the presence of a C6 template, form a detecta-
ble ligation product. This interpretation is further
supported by the lower mass of the C7-1 ligation product
compared to the C7 ligation product that would be formed
by the full-length C7 oligonucleotide in the presence of a
C7 template. Conversely, PCR/LDR of the avirulent par-
ent, BP369, generated an abundant ligation product with
the C7 discriminating oligonucleotide, as expected. How-
ever, as above, a faint ligation product produced with the
C6  discriminating oligonucleotide preparation, with
higher mass than expected for the C6 product, can be
attributed to synthesis errors that result in rare oligonucle-
otides (denoted "C6+1") with one additional cytosine at
the 3' end. Ligation products formed by synthesis artifacts
could be easily distinguished from legitimate products by
their characteristic electrophoretic mobility. Equivalent
ligation products were obtained whether reactions con-
tained one (uniplex) or both (multiplex) discriminating
oligonucleotides (Figure 1B).
In order to examine the ability of PCR/LDR to detect infre-
quent HPT alleles in a mixed population of templates,
bvgS PCR product from BP369 was mixed with bvgS PCR
product from BP370 in a series of dilutions (Figure 1C).
The C7 allele from BP369 could be detected in a multiplex
reaction when present at 100-fold lower concentration
than the C6 allele, but not at 500-fold lower concentra-
tion. This sensitivity is similar to that observed for PCR/
LDR detection of single nucleotide HPT variants on syn-
thetic templates [28]. Thus, this method can detect phase
variants that comprise as little as 1% of the sample tem-
plate.
Detection by PCR/LDR of HPT alleles in bvgS Figure 1
Detection by PCR/LDR of HPT alleles in bvgS. (A) 
Schematic of BP370 and BP369 genomic DNA templates 
aligned with LDR oligonucleotides. Purple text denotes the 
HPT; green star indicates the FAM fluorophore; cyan text 
shows non-hybridizing bases used for size discrimination of 
oligos. HPT length is six cytosines (C6) in BP370, and seven 
cytosines (C7) in BP369. Covalent bonds (diagonal lines) are 
catalyzed by DNA ligase only if the discriminating and com-
mon oligonucleotides are immediately adjacent when hybrid-
ized to the template. (B) Raw capillary electrophoresis data 
for ligation products (green) and molecular weight standards 
(red) displayed as if an electrophoretic gel image. Source of 
template genomic DNA is indicated across the top of the 
panel. BP370* is a culture derived from BP370 that contains a 
minority population of C7 phase variants. All reactions con-
tained common oligonucleotide; discriminating oligonucle-
otides are indicated above each lane (C6 and C7 indicate 
uniplex reactions, C6 + C7 indicates multiplex). Ligation prod-
ucts (arrows) are labeled as follows. C7 and C6 indicate the 
products formed by ligation of the common oligonucleotide 
to the C7 and C6 discriminating oligonucleotides, respectively. 
C6+1 denotes the product formed by ligation of the common 
oligonucleotide to a synthesis artifact in the C6 discriminating 
oligonucleotide preparation that has one extra 3' C. Similarly, 
C7-1 denotes the product formed by ligation of the common 
oligonucleotide to a synthesis artifact in the C7 discriminating 
oligonucleotide preparation that has one fewer 3' C. This 
notation is used throughout the figures of this manuscript. 
(C) Raw capillary electrophoresis displayed as in panel B. All 
lanes are multiplex reactions using C6 and C7 discriminating 
oligos with the genomic DNA template indicated above each 
lane. Lanes 3–6 show the ratio of PCR amplified bvgS from 
BP369 to bvgS from BP370. Ligation products are labeled as 
in panel B. (D) Partial trace of directly sequenced bvgS PCR 
product from BP370*. Purple arrow indicates the point in the 
sequence trace after which peak shadowing, indicative of a 
mixture of HPT alleles, can be observed.
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To assess the sensitivity of PCR/LDR in identifying a mix-
ture of alleles in a bacterial sample, genomic DNA was
prepared from a culture of BP370*, a strain that was iso-
lated during a single passage of BP370 on BG blood agar.
As the result of spontaneous mutation, BP370* contains a
mixture of virulent and avirulent phase variants, as deter-
mined by plating on BG blood agar. Multiplex PCR/LDR
of this sample yielded ligation products with both the C6
and C7 discriminating oligonucleotides, verifying that the
genomic DNA preparation from this strain contained a
mixture of C6 and C7 bvgS alleles (Figure 1B). This result
was further validated by DNA sequencing of the bvgS PCR
product from the same DNA preparation (Figure 1D).
Thus, cultures composed of mixed populations with dis-
tinct HPT alleles, such as those that arise during labora-
tory passage of B. pertussis, are readily identifiable by PCR/
LDR.
The rate of repeat expansion and contraction due to DNA
polymerase slippage rises with increasing repeat number
[30]. Therefore, high-fidelity PCR amplification is critical
to this allelic detection scheme, especially for long HPT
tracts. In order to asses the fidelity of PCR/LDR, a region
of bapC containing a G10 tract was amplified using either
high-fidelity Pfu DNA polymerase or the relatively lower
fidelity Taq DNA polymerase, then screened by LDR (as
described below). After 30 cycles of PCR, LDR of the Pfu-
amplified template showed no tract length variation, but
LDR of the Taq-amplified template detected tracts of 9, 10,
and 11 guanosines (Additional file 2). Subsequent rounds
of PCR product dilution and re-amplification with Pfu
polymerase did not yield any detectable HPT variants
(contractions) until the third round (90 cycles of PCR);
tract expansions were not observed even after 120 cycles.
Therefore, in a standard PCR/LDR experiment (30 cycles
of PCR), there is negligible variation in HPTs 10 bases or
shorter due to polymerase replication error when Pfu
DNA polymerase is utilized. These results indicate that
tract length heterogeneity detected by PCR/LDR as per-
formed in this study accurately reflects HPT length heter-
ogeneity in vivo.
Identification of putative phase-variable genes in 
Bordetella genomes
To identify putative phase-variable genes in B. pertussis,
the genome sequence of the Tohama I strain [3] was
screened for HPTs. Statistical analysis of sequence compo-
sition with a second order Markov model indicated that
C/G HPTs more than 8 bases long, and A/T HPTs more
than 5 bases long were observed more frequently than
would be expected by chance in the B. pertussis and B.
bronchiseptica genome sequences (Figure 2). To be con-
servative, the threshold for calling A/T HPTs was raised to
greater than 7, due to the relative stability of shorter
repeats in experimental systems [31]. Although shorter
HPTs are known to be phase-variable in B. pertussis (e.g.,
C6 in bvgS), only genes associated with HPTs exceeding
these conservative thresholds were classified as putative
phase-variable genes in this computational screen.
Because only a single B. pertussis genome sequence is avail-
able, it was not possible to search for polymorphic HPTs
between strains of this species. However, because B. per-
tussis and B. parapertussis recently evolved from B. bron-
chiseptica  [2-4], orthologous sequences of these three
species are highly conserved. Of particular relevance to
this study, single nucleotide indels between the B. pertussis
and B. bronchiseptica genomes are found at fewer than 1 in
10,000 bases. Therefore, any HPTs that are polymorphic
among these three species were strong candidates for
phase-variable loci. In accordance with this logic, the B.
parapertussis and B. bronchiseptica genomes [3] were also
screened for HPTs, and for each tract, the orthologous
locus was examined in all three species. This screen
resulted in the identification of 69 HPT loci among the
three species (Table 1; Additional files 3, 4, and 5).
Because sequence composition differs in mobile genetic
elements, HPTs in prophage or insertion elements were
excluded from further analysis.
Among the three species, 51 (74%) of the HPT loci were
found to be polymorphic, meaning that the orthologous
locus is present in at least two genomes and HPT length
Observed/expected plots of different length HPTs in the B.  pertussis and B. bronchiseptica genomes Figure 2
Observed/expected plots of different length HPTs in 
the B. pertussis and B. bronchiseptica genomes. 
Expected frequencies of A and C HPTs in the B. pertussis 
Tohama I (Bp) and B. bronchiseptica RB50 (Bb) genomes were 
calculated for a range of tract lengths using a second order 
Markov model. For each tract length, observed/expected val-
ues were determined by dividing the actual number of HPTs 
greater than or equal to that tract length by the expected 
number. The observed/expected value for A HPTs drops to 
zero at tract length of 10 because neither genome harbors an 
A HPT with more than 9 bases.
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) Table 1: Significant HPTs in B. pertussis, B. bronchiseptica, and B. Parapertussis
B. pertussis Tohama I B. bronchiseptica RB50 B. parapertussis 12822
HPTa ORFb Allelec ORF Allele ORF Allele Gene Base Poly-
morphicd
Loce Promoter 
overlapf
Functional categoryg
11 BP2991 7 BB4384 9 BPP3911 9 A/T y I L Biosynthesis of cofactors, carriers
12 BP3682 8 BB0097 8 BPP0098 8 A/T n I M Hypothetical protein
13 BB0618, BB0619 8 BPP0612, 
BPP0613
7 A/T y I H Global regulatory functions
14 BB0622 8 BPP0616 8 A/T n I M Conserved hypothetical
15 BP3151 9 BB0875 8 BPP0790 8 A/T y I L Cell envelope
16 BB0999 8 BPP0906 8 A/T n I L Transport/binding proteins
17 BP0880 7 BB1564 8 BPP2167 7 A/T y I L Periplasmic/exported/lipoproteins
18 BP2792 8 BB1918 8 BPP2471 8 A/T n I H Hypothetical protein
19 BP2908 8 BB1935 8 BPP2488 8 aroG A/T n I L Amino acid biosynthesis
20 BP2735 8 BB2036 8 BPP2594 8 A/T n I H Conserved hypothetical
21 BP2539 8 BB2083 8 BPP2640 8 A/T n I L Cell envelope
23 BP1487 8 BB2136 8 BPP1948 8 smoMh A/T n I M Transport/binding proteins
24 BP1419 8 BB2605 8 BPP1527 8 rpsB A/T n I M Ribosome constituents
25 BP1245 9 BB3248 8 BPP1860 11 A/T y I M Conserved hypothetical
26 BP1231 8 BB3262 8 BPP1846 8 A/T n I H Cell envelope
27 BP2399 8 BB3715 8 BPP3264 7 A/T y I L Global regulatory functions
28 BP2425 8 BB3740 8 BPP3289 9 A/T y I M Periplasmic/exported/lipoproteins
29 BP0858 9 BB3824 8 BPP3373 9 A/T y I H Hypothetical protein
30 BP0856 8 BB3826 8 BPP3376 10 bfrD A/T y I L Adaptation
31 BP3399 8 BB3987 8 BPP3552 8 A/T n I M Conserved hypothetical
32 BB4499 8 BPP4026 8 A/T y I H Conserved hypothetical
33 BP0347 8 BB4655 8 BPP4185 8 bhuR A/T n I K Adaptation
34 BP3870 8 BB5012 8 BPP4424 8 A/T n I M Hypothetical protein
41 BP2506, BP2507 9 BB3941, BB3942 9 BPP3494 9 A/T n I N Macromolecule synthesis, modification
43 BP2863 9 BB1178 9 BPP0966 9 A/T n I H Conserved hypothetical
50 BP0939 8 A/T y I L Conserved hypothetical
51 BP0964 8 BB3455 9 BPP3115 9 A/T y I L Hypothetical protein
52 BP0966 8 BB3453 9 BPP1655 9 sbp A/T y I M Transport/binding proteins
56 BP2936 8 BB1280 8 BPP1064 9 A/T y I M Periplasmic/exported/lipoproteins
60 BP0598 6 BB0289 6 BPP0286 8 A/T y I L Conserved hypothetical
64 BB1238 7 BPP1024 8 A/T y I M Energy metabolism, carbon
68 BP2084 7 BB3340 7 BPP1768 8 A/T y I H Conserved hypothetical
69 BP1811 6 BB3216 6 BPP1892 8 kdgT A/T y I M Transport/binding proteins
70 BP1781 6 BB2260 7 BPP2012 8 A/T y C Conserved hypothetical
73 BPP2251 8 bapA A/T y I L Cell envelope
76 BP1893, BP1894i A2CA6 BB2980, BB2979i A2CA6 BPP3014, 
BPP3013i
9 A/T y I H Cons. hypo.; Global reg. functions
79 BP3852 nrj BB4994 7 BPP4406 8 katA A/T y I L Protection responses
83 BB3111, BB3112i 8 BPP1616, 
BPP1617i
8 A/T n I L Cell envelope; hypothetical protein
84 tRNA-Asn, tRNA-Thri 8 tRNA-Asn, tRNA-Thri 8 tRNA-Asn, 
tRNA-Thri
8 A/T n I U Macromolecule synthesis, modification
1 BB0357 11 BPP0354 8 C/G y I M Periplasmic/exported/lipoproteinsB
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2 BB1186 10 BPP0974 7 C/G y I M Periplasmic/exported/lipoproteins
3 BP1568 13 BB1658 22 BPP2262 C6TC3 fim3 C/G y I K Cell envelope
4 BP2738 11 BB2033 7 BPP2591 7 bapCh C/G y C Cell envelope
5 BB3110 17 BPP1618 nr C/G y C Cell envelope
6 BP1201 9 BB3291 17 tcfA C/G y C Cell envelope
7 BB3425 15 BPP1683 10 fimN C/G y I K Cell envelope
8 BP2674 7 BB3426 13 BPP1682 9 fimX C/G y I K Cell envelope
9 BP1119 12 BB3674 20 BPP3222 C9TC8 fim2 C/G y I K Cell envelope
10 BP3037, BP3038 11 BB4210, BB4211 11 BPP3764, 
BPP3765
9 C/G y I N Hypothetical protein
22 BP1487 9 BB2136 C5GC3 BPP1948 C5GC3 smoMh C/G y C Transport/binding proteins
35 BP0146 15 BB4482 6 BPP4009 6 C/G y I H Hypothetical protein
36 BP1766 10 BB2245 G6TG3 BPP1997 8 C/G y I N Central intermediary metabolism
37 BP1879 10 BB2993 3 BPP3027 2 fhaB C/G y C Cell envelope
39 BP1961 11 BB1784 nr BPP2333 nr C/G y I H Energy metabolism, carbon
40 BP2483 10 BB3920 C2AC5 BPP3471 C2AC5 kdpD C/G y C Global regulatory functions
42 BP2595 12 BB2360 G3TG3 BPP1295 G3TG3 C/G y C Macromolecule degradation
44 BP2896 9 BB1947 8 BPP2500 7 C/G y I H Hypothetical protein
45 BP3224 9 BB4011 6 BPP3576 nr C/G y C Energy metabolism, carbon
46 BP3474 13 BB0944 9 BPP0850 7 C/G y I M Conserved hypothetical
59 BP3624 7 BB0040 7 BPP0040 9 C/G y I H Degradation of small molecules
61 BP0520 6 BB0444 5 BPP0443 9 C/G y I L Periplasmic/exported/lipoproteins
62 BP0426 nr BB0472 7 BPP0472 13 cspA C/G y I L Adaptation
65 BB1351 9 BPP1135 9 C/G n I H Global regulatory functions
66 BP1047 7 BB1361 8 BPP1145 10 C/G y I M Periplasmic/exported/lipoproteins
67 BP1160 8 BB2684 8 BPP1607 11 C/G y C Periplasmic/exported/lipoproteins
71 BP1793 2 BB2270 18 BPP2022 G12TG2AG3 C/G y I L Cell envelope
75 BP1660 G5CG2CG3 BB2741 8 BPP2745 12 sphB2 C/G y C Cell envelope
78 BB4881 G4ACG2 BPP4294 14 C/G y I H Global regulatory functions
82 BP2738 14 BB2033 35 BPP2591 C6TC5 bapCh C/G y C Cell envelope
a HPT number is an arbitrarily assigned unique ID. Table is sorted by order in the B. bronchiseptica RB50 genome.
b Identifier of ORF that is either contains or is downstream of the HPT. Empty cell indicates that no orthologous sequence exists in that genome.
c Numbers are length of HPTs. Sequences are given when the tract contains a substitution relative to alleles in the other genomes.
d "y" denotes HPT length polymorphism among the three sequenced genomes.
e "I", located in intergenic region; "C", located in coding sequence
f Probability that the HPT overlaps a promoter coded as follows: H, high; M, moderate; L, low; N, not near a promoter (located in 3' region of convergently transcribed genes); K, known to overlap 
experimentally defined promoter; U, undetermined. Values were not assigned to coding HPTs. See Methods for definitions of classes.
g Functional categories from MultiFun classification system as assigned by Parkhill, et al. [3]
h Two separate HPTs are found in these genes.
i HPT is upstream of two features by a similar distance.
j "nr" indicates that no HPT is found in the orthologous region.
Table 1: Significant HPTs in B. pertussis, B. bronchiseptica, and B. Parapertussis (Continued)BMC Genomics 2007, 8:122 http://www.biomedcentral.com/1471-2164/8/122
Page 7 of 16
(page number not for citation purposes)
differs between them (Table 1). As a result, some of the
HPTs in one or two genomes have fewer bases than the
selection threshold. Twelve of the HPTs were found in
coding regions, with the potential to influence protein
length or amino acid sequence. In order to identify tracts
that could affect transcriptional regulation, intergenic
HPTs were assigned a likelihood of overlapping a pro-
moter, with those located between 21 and 80 nt upstream
of the start codon of an ORF being the most likely candi-
dates (Table 1; Additional files 3, 4, and 5). Nineteen
HPTs are in this class, including those upstream of the
four fimbrial major subunit genes where they have been
shown to overlap the functional promoters [26,27].
Although it is more than 80 nt upstream of the start
codon, the HPT upstream of bhuR was also considered
very likely to influence transcription because it maps five
bases upstream of the experimentally defined -35 box
[32]. In most cases, due to orientation or relative proxim-
ity of flanking CDSs, intergenic HPTs could be associated
with the regulatory region of a single gene. Intergenic
HPTs located in the 3' region of two ORFs or more than
150 nt upstream of the closest ORF start codon are
unlikely to be involved in regulation.
Sixteen HPTs were associated with genes encoding cell
envelope proteins, and 8 were associated with genes
encoding periplasmic or exported proteins, or lipopro-
teins, for a total of at least 24 genes whose putative prod-
ucts are possible targets for host cell interaction and
immune surveillance. Polymorphisms among the three
species were more frequent among G/C HPTs (29/30)
than among A/T HPTs (21/39) (two-tailed p = 0.00007,
Fisher's exact test), but this result could be due to the
longer tract length of G/C HPTs analyzed here. Due to
gene loss in B. pertussis, 13 of the Bordetella HPT loci iden-
tified here are not present in the Tohama I genome. Also,
the genes linked to two HPT loci identified in the other
species are present in Tohama I, but they are not associ-
ated with an orthologous HPT, and two other loci have
stabilized HPTs in Tohama I. In summary, we assessed B.
pertussis to have 36 HPTs that are potentially subject to
phase variation, 10 by disrupting an open reading frame,
and 26 with high or moderate likelihood of affecting tran-
scriptional regulation. By similar logic, B. bronchiseptica
and B. parapertussis were assessed to have 43 and 42 puta-
tive phase-variable HPTs, respectively.
Identification of B. pertussis phase-variable HPTs by PCR/
LDR
In order to detect rare tract length alleles in the B. pertussis
population, and identify variations that may be associated
with specific time periods or geographical locations, a
large collection of isolates (see below) was assayed for a
selected group of HPTs. Six loci were chosen from the list
of Bordetella HPTs for further investigation of allelic poly-
morphism (Table 1). Selection of these loci was biased
toward HPTs in genes encoding predicted cell envelope
proteins (four HPTs) and HPTs that were polymorphic
among the three sequenced genomes (five HPTs). Three
HPTs – upstream of fimX (BP2674), BP0880, and bhuR –
are predicted to influence transcriptional regulation. HPTs
associated with the other three loci – sphB2 (BP1660), tcfA
(BP1201), and bapC (BP2738) – are located within the
coding sequence. Because HPTs shorter than the threshold
lengths used here have been shown to be phase-variable
in B. pertussis (e.g., bvgS), three HPT loci with fewer than 9
C/G base pairs were also chosen for analysis (Table 2).
HPTs in BP3651 and BP0059 are polymorphic among the
sequenced genomes, and the third, upstream of ptxA, is
not (Table 2). The HPTs of these nine loci were genotyped
by PCR/LDR in a collection of 90 B. pertussis strains
encompassing a considerable degree of temporal (70
Table 2: Additional B. pertussis, B. bronchiseptica, and B. parapertussis HPTs analyzed in this study
B. pertussis 
Tohama I
B. bronchiseptica 
RB50
B. parapertussis 
12822
HPT 
numa
ORFb Allelec ORF Allele ORF Allele Gene Base Poly-
morphicd
Loce Promoter 
overlapf
Functional categoryf
47 BP0059 8 BB0530 6 BPP0525 6 C/G y C Global regulatory functions
81 BP1877 6 BB2995 6 BPP3029 6 bvgS C/G n C Global regulatory functions
57 BP3651 8 BB0066 6 BPP0066 6 C/G y I H Cell envelope
85 BP3783 6 BB4890 6 BPP4304 6 ptxA C/G n I K Periplasmic/exported/
lipoproteins
a HPT number is an arbitrarily assigned unique ID. Table is sorted by order in the B. bronchiseptica RB50 genome.
b Identifier of ORF that is either contains or is downstream of the HPT. Empty cell indicates that no orthologous sequence exists in that genome.
c Numbers are length of HPTs. Sequences are given when the tract contains a substitution relative to alleles in the other genomes.
d "y" denotes HPT length polymorphism among the three sequenced genomes.
e "I", located in intergenic region; "C", located in coding sequence
f Probability that the HPT overlaps a promoter coded as follows: H, high; K, known to overlap experimentally defined promoter.
Values were determined only for coding HPTs. See Methods for definitions of classes.
g Functional categories from MultiFun classification system as assigned by Parkhill, et al. [3]BMC Genomics 2007, 8:122 http://www.biomedcentral.com/1471-2164/8/122
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years) and geographic (4 continents) diversity (Additional
file 6).
If Tohama I were a representative B. pertussis strain, variant
alleles of each HPT in other strains would be most often
either one base pair longer or shorter than the Tohama I
allele. Thus, for each locus, three discriminating oligonu-
cleotides were synthesized: one each targeting the HPT in
the Tohama I allele, the -1 allele (relative to Tohama I),
and the +1 allele (Additional file 7). The BP3651, fimX,
BP0880, BP0059 and sphB2 HPTs were screened with uni-
plex reactions that contained the single discriminating oli-
gonucleotide that targets the Tohama I allele, and the
FAM-labeled common oligonucleotide. The remaining
HPTs were screened by multiplex PCR/LDR reactions in
which all three discriminating oligonucleotides were
mixed with a FAM-labeled common oligonucleotide.
Strains yielding PCR/LDR profiles different from Tohama
I were further analyzed by sequencing the PCR product
containing the variable HPT. In cases where no ligation
products were detected, HPT length was determined by
sequencing.
Among the strains examined, the HPTs in BP0880, sphB2,
and bhuR were not polymorphic, indicating that they are
stable in the B. pertussis population (Figure 3; Additional
files 8, 9, and 10). Two HPTs varied in only a single B. per-
tussis strain. The coding HPT in BP0059 contained one
additional base in WCH21, an isolate from Australia (Fig-
ure 3 and Additional file 11). This HPT is the site of a
frameshift mutation that truncates the ORF in B. pertussis
Tohama I. The single base insertion in WCH21 restores
the reading frame and is predicted to result in a full-length
protein; all other strains assayed carry the frameshifted
allele. The HPT upstream of ptxA varied by the addition of
a single base in strain 03588, isolated in Italy in 1993 (Fig-
ure 3 and Additional file 12). This insertion increases the
distance between the predicted -35 and -10 boxes of the
ptx-ptl operon [33]. Changing the distance between these
regulatory elements by as few as two bases has been
shown to reduce dramatically transcription of this key
toxin expression locus, suggesting that the HPT variation
in 03588 may have significant consequences for expres-
sion [34].
The five HPTs described above maintained a constant
length over the duration of each B. pertussis batch culture
experiment (representing 109 bacteria). Since the detec-
tion limit of the assay is 1 variant allele in 100, the propor-
tion of mutants after 30 [log2(109)] generations has an
upper bound of 0.01. Using the mathematical model
developed by Saunders, et al. [35], the maximum phase
variation rate for these loci, assuming equal forward and
back mutation rate and no fitness difference, is 6.7 × 10-4
per generation.
HPT variation in fimX and other fimbrial major subunit 
gene promoters
In seven strains, the HPT upstream of fimX differed from
the Tohama I allele (C7) by the addition of a single base
(Figure 3; Additional files 13 and 14). After excluding rep-
licate isolates, four independent strains with the longer
allele remained. This HPT is also known as the "C-stretch"
motif of a previously identified fimbrial gene promoter
element, which also contains the conserved "fim box"
[26,27]. The length of the C-stretch in the fim2 and fim3
Representative PCR/LDR results for HPTs in fimX, BP0059,  BP0880, sphB2, ptxA, and bhuR Figure 3
Representative PCR/LDR results for HPTs in fimX, 
BP0059, BP0880, sphB2, ptxA, and bhuR. Raw capillary 
electrophoresis data for ligation products (green) and molec-
ular weight standards (red) displayed as if an electrophoretic 
gel image. Assayed locus is indicated at the top of each panel; 
strain and length of its HPT allele are noted above each lane. 
Representative LDR results are depicted here; for complete 
data from all strains see Additional files 8, 9, 10, 11, 12, and 
13. BP0880, BP0059, fimX, and sphB2 HPTs were screened 
by uniplex LDR reactions containing only the discriminating 
oligonucleotide that targets the Tohama I sequence. The ptxA 
and bhuR HPTs were screened by multiplex reactions that 
contain all three discriminating oligonucleotides. Letters in 
teal indicate molecular weight standards as labeled in the 
corresponding supplementary figures. Ligation products 
(arrows) are labeled using the notation described in the leg-
end to Figure 1. The open arrowhead indicates a synthesis 
artifact in the BP0059 common oligonucleotide preparation.
&
&
*
*
7
&
&
$
$
ILP; %3 %3
%
S
H


&

%
S
H


&

:
&
+


*

:
&
+

*

%
S
H



7

%
S
H



7

&
&
&
%
&
&
&
$
SW[$ VSK%




&

%
S
H


&

%
S
H



*

%
S
H



*

%
S
H


$

%
S
H



$

EKX5
$
$
$
$
*BMC Genomics 2007, 8:122 http://www.biomedcentral.com/1471-2164/8/122
Page 9 of 16
(page number not for citation purposes)
promoters has been shown to influence transcriptional
activity [26,27]. Furthermore, deliberate mutation of the
C-stretch upstream of fimX affected transcription of that
gene [26]. In order to examine whether fimX expression
differed between the allelic variants in our collection,
quantitative RT-PCR was used to assay fimX  transcript
abundance in a sample of strains harboring C8 versus C7
tracts. Linear regression analysis showed a strong correla-
tion (R2 = 0.611) between transcript abundance and tract
length, in which strains with the C8 HPT had an average
fimX transcript abundance 3.8-fold lower than those with
a C7 HPT (p = 0.0137) (Additional file 14). Although this
result strongly suggested that a single base length poly-
morphism in this HPT may influence fimX expression, dif-
ferential effects due to cis- or trans-regulatory factors
cannot be ruled out. However, the sequences of the 64
bases upstream of the C-stretch and 87 bases downstream,
including the translational start site, did not differ
between the strains examined. Among the 51 independ-
ent clinical isolates from the United States and the Neth-
erlands for which vaccine history was known, all three of
the C8 fimX HPT alleles were from strains isolated prior to
the introduction of vaccination (1949 in the United
States, and 1953 in the Netherlands; two-tailed p  =
0.0146, Fisher's exact test).
Other B. pertussis and B. bronchiseptica fimbrial major sub-
unit genes exhibit allelic polymorphisms in coding
regions [36-38] and in the long cytosine HPTs (up to C19
in B. bronchiseptica fim3) in their promoters [26,27,39].
Because the data above suggest a shift in fimX HPT alleles
subsequent to vaccine introduction, the HPTs upstream of
fim2 and fim3 were assayed for evidence of a concomitant
change. Because HPTs greater than 16 nt are not reliably
measured by LDR [28], these HPTs were characterized by
direct sequencing of PCR products, recognizing that the
generation of slippage products in the PCR and sequenc-
ing reactions remains a potential source of experimental
error.
HPT lengths for fim2  ranged in this set of B. pertussis
strains from 10 to 15. As with fimX HPT length polymor-
phisms, the pre-vaccine strains (median = 13.5) had sig-
nificantly longer fim2  HPTs than post-vaccine strains
(median = 11; p = 0.0339, Mann-Whitney U-test; Addi-
tional file 14). Likewise, HPT lengths for fim3 ranged in
this sample from 13 to 18; pre-vaccine strains (median =
14.5) tended to have longer tracts than post-vaccine
strains (median = 13), but this difference did not achieve
statistical significance (p = 0.0771, Mann-Whitney U-test).
HPTs that varied during a single round of culture
The HPTs of tcfA, bapC, and BP3651 exhibited tract length
variation between strains, and within genomic DNA sam-
ples derived from cultures of 109 bacteria grown from sin-
gle colonies over 30 [log2(109)] generations (Additional
file 15). Variant alleles of the HPT upstream of BP3651
were found in six strains (Figure 4; Additional files 15 and
16). The atypical B. pertussis strain, 18323, represented by
three separate isolates, harbored a mixture of G9 and G10
alleles. Three other independently isolated strains dis-
played a mixture of G8 and G9 alleles. In all other strains
in this collection, only the G8 allele was detected, suggest-
ing that this HPT may be unstable only when its length
exceeds a critical threshold of 8 bases. In order to deter-
mine whether allelic variation was present in smaller pop-
ulations founded by a single cell, five independent single
colonies (approximately 107 bacteria; data not shown) of
two variable strains, Bpe354 and Bpe16, were assayed by
colony PCR/LDR. In all cases, each of the single colonies
yielded mixed LDR profiles, indicating that allelic varia-
tion in the BP3651 HPT arises over the approximately 23
[log2(107)] generations required to produce a macro-
scopic colony.
The predominant bapC HPT allele in 76/90 isolates was
G11, but almost all of these also harbored a detectable
fraction of G10 and G12 alleles (Figure 6 and Additional
file 18). Six strains carried primarily the G10 allele, two
Representative PCR/LDR data for the BP3651 HPT Figure 4
Representative PCR/LDR data for the BP3651 HPT. 
(A) Raw capillary electrophoresis data for ligation products 
from BP3651 uniplex PCR/LDR (green) and molecular weight 
standards (red) displayed as if an electrophoretic gel image. 
Strains are indicated above each lane. Ligation products 
(arrows) are labeled using the notation described in the leg-
end to Figure 1. Letters in teal indicate molecular weight 
standards as labeled in Additional file 16. (B) Partial traces 
from direct sequencing of BP3651 PCR products. Strain and 
alleles are noted above each sequence trace. Purple arrows 
indicate the point in the sequence trace after which peak 
shadowing, indicative of a mixture of HPT alleles, can be 
observed.
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carried primarily the G9 allele, and four carried primarily
the G8 allele, but in most of these cases, a mixture of alle-
les was detected. In many cases, mixed allelic content was
verified by sequencing (Figure 6). In order to assess allelic
variation in small populations founded by a single cell, 93
independent Bpe60 colonies, each containing approxi-
mately 1 × 107 bacteria, were assayed by colony PCR/
LDR. In every case, multiple alleles were detected, with the
G11 allele predominating, but G10, G12, and in some
cases G13 alleles also present (Additional file 19), indicat-
ing that allelic variation in the bapC HPT also arises
within 23 generations. The G11 tract, as annotated in the
Tohama I genome sequence, causes a shift in the reading
frame that is predicted to result in a truncated BapC pro-
tein. However, a single base contraction of the HPT would
restore the reading frame, leading to synthesis of a full-
length protein.
The predominant tcfA allele in 82/90 strains was G9, but
the G8 allele was detected as a minor allele in 75 of these
(Figure 5 and Additional file 17). One strain, Bpe122,
yielded approximately equal numbers of G8 and G9 alle-
les. Five strains carried primarily the G10 allele, but four
of these also harbored a detectable fraction of G9 and G11
alleles. One- or two-base insertions into the G9 HPT,
beginning at codon 130 of the tcfA ORF, alter the reading
frame, and presumably result in a truncated, non-func-
tional Tcf protein. Stability of the tcfA HPT was further
assessed by cloning PCR products containing the HPT
into a plasmid in E. coli. Eight independent E. coli clones
harboring PCR products from the Bpe354 genomic DNA
preparation, which carried predominantly G10 alleles,
but detectable G9 alleles, were assayed by colony PCR/
LDR. Five of the clones carried a mixture of alleles similar
to the original Bpe354 genomic DNA preparation, while
three clones carried a mixture of G10 and G11 alleles,
indicating that allelic contraction and expansion at this
locus occurs in E. coli (data not shown).
Discussion
B. pertussis is unusual among bacterial pathogens in its
limited genomic diversity. Multiple methods, including
MLST, MLEE, and CGH, have found that B. pertussis is
highly clonal with very few genomic differences, even
among temporally and geographically diverse strains
[4,10,11]. Phase variation could be an important mecha-
nism in B. pertussis for generation of phenotypic diversity
in the absence of genome plasticity. In fact, prior to this
study, a small number of key virulence phenotypes of B.
pertussis were already known to be phase-variable.
Representative PCR/LDR data for the bapC HPT Figure 6
Representative PCR/LDR data for the bapC HPT. 
Raw capillary electrophoresis data for ligation products from 
bapC multiplex PCR/LDR (green) and molecular weight 
standards (red) displayed as if an electrophoretic gel image. 
Strains and HPT allele lengths are indicated above each lane. 
Ligation products (arrows) are labeled using the notation 
described in the legend to Figure 1. Letters in teal indicate 
molecular weight standards as labeled in Additional file 18. 
(B) Representative traces from direct sequencing of bapC 
PCR products. Strain and alleles are noted above each 
sequence trace. Purple arrows indicate the point in the 
sequence trace after which peak shadowing, indicative of a 
mixture of HPT alleles, can be observed.
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Representative PCR/LDR data for the tcfA HPT Figure 5
Representative PCR/LDR data for the tcfA HPT. (A) 
Raw capillary electrophoresis data for ligation products from 
tcfA multiplex PCR/LDR (green) and molecular weight stand-
ards (red) displayed as if an electrophoretic gel image. Strains 
are indicated above the lane. Ligation products (arrows) are 
labeled using the notation described in the legend to Figure 1. 
Letters in teal indicate molecular weight standards as labeled 
in Additional file 17. (B) Representative traces from direct 
sequencing of tcfA PCR products. Strain and alleles are noted 
above each sequence trace. Purple arrow indicates the point 
in the sequence trace after which peak shadowing, indicative 
of a mixture of HPT alleles, can be observed.
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This study focused on the identification and characteriza-
tion of HPTs, because they are prone to expansion and
contraction and often associated with bacterial phase-var-
iable loci. Evidence of phase variation can be obtained by
demonstrating repeat length polymorphism within multi-
ple genomes from the same species, or closely related spe-
cies as in this study. Scanning multiple related genomes
has the added benefit of identifying polymorphic, puta-
tive, phase-variable loci that fail to meet the identification
threshold in one strain but meet it in another. For exam-
ple, if only the TohamaI genome had been scanned, 40
HPTs would have been identified,; however, the compar-
ative approach identified 12 more HPTs that are shorter
than the threshold in B. pertussis but meet the threshold in
at least one of the closely related Bordetella genomes.
The comparative approach, while identifying HPTs that
have changed at least once since the divergence of the two
genomes, does not address the key issue of allelic varia-
tion rate. Are these differences stable over the long time
periods that differentiate bacterial lineages, or do they
fluctuate rapidly, with each genome sequence providing
only a snapshot of the genome at a specific point in time?
An estimate of HPT variation frequency can be obtained
by measuring repeat length in multiple genomes, and
doing so with a method sensitive enough to detect rare
variants in a mixture of alleles. PCR/LDR is an ideal
method for detecting rare genotypes as it can clearly delin-
eate numerous genotypes within a mixed sample. While
the assay is not quantitative, its sensitivity allows detec-
tion of one variant HPT in 100 ([28]; this study). With a
sequencing-based approach, assuming a Poisson distribu-
tion, 300 clones would need to be analyzed to have a 99%
chance of detecting a variant allele representing 1% of the
sample.
The frequency of allelic variation differed greatly among
the nine HPTs genotyped in this study. Three HPTs were
invariant among the 90 B. pertussis isolates, two differed in
a single strain, and one differed between strains isolated
during different eras. Because no single genomic DNA
preparation harbored a detectable mixture of HPT alleles,
a maximum mutation rate of 6.7 × 10-4 mutations per gen-
eration was inferred for these six loci. The actual mutation
rate could be significantly lower, but accurate determina-
tion would require identification of cultures containing
variant alleles, and estimation of the relative fitness of
each genotype, both of which are impractical due to the
low apparent rate of variation and lack of a known selecta-
ble phenotype. Three HPTs exhibited allelic polymor-
phism within single colonies. The HPT in BP3651 was
variable within a single culture only in strains with alleles
longer than C8, leading us to speculate that an HPT might
become relatively unstable with the addition of a single
base. The mechanisms that regulate the frequency of HPT
phase variation are not clearly understood, but conditions
that influence the activity of the mismatch repair pathway
have been shown to affect the frequency of phase varia-
tion [40]. Although the mutation rate at the BP3651, tcfA,
and bapC HPTs is apparently much higher than for the
other HPTs examined here, accurate determination of
these rates would require quantitative estimates of the
proportion of each allele, which is not possible using
LDR. The relative fitness of each genotype is also a key
parameter in this calculation [35], but because stable gen-
otypes cannot be isolated in culture, these measurements
cannot easily be made. However, fitness differences would
reduce frequency of deleterious alleles, making the muta-
tion rate appear lower than it actually is.
The discovery here of a B. pertussis strain with an expanded
HPT in a region of the ptx promoter known from muta-
tional studies to be critical for transcriptional activity [34]
suggests that ptxA expression may be atypical in this strain.
Although numerous studies have documented allelic var-
iation in the coding region of ptxA (e.g., [36,41,42]), only
one study focused on potential regulatory polymor-
phisms in the ptx promoter region, identifying rare single
nucleotide polymorphisms further upstream of ptxA, but
not in the HPT [43]. Allelic shifts subsequent to the intro-
duction of vaccination in the ptxA coding region support
a model of vaccine-driven evolution [44]. Perhaps modi-
fied expression of PT could also confer a fitness advantage
in a vaccinated host population. These possibilities
deserve and require further investigation.
Two genes encoding autotransporter family proteins had
the most highly variable HPTs among the loci assayed.
The tcfA gene encodes tracheal colonization factor (Tcf), a
secreted protein produced by B. pertussis [45]. Disruption
of this gene resulted in a 10-fold reduction in colonization
of a mouse model, suggesting that it is an important viru-
lence determinant [45]. The phase-variable HPT is located
in the tcfA open reading frame such that expansions and
contractions of the tract would result in the reversible
truncation, and presumed inactivation, of the Tcf protein
product. This HPT is the location of the frameshift poly-
morphism previously identified in the tcfA5 allele, which
was proposed to represent a tcfA phase variant [41]. The
PCR/LDR results suggest that, within a culture of B. pertus-
sis, only a fraction of cells express full-length TcfA. The
prevalence of antibodies against TcfA in human popula-
tions has not been addressed, but the existence in the B.
pertussis population of multiple tcfA alleles that encode
different protein variants suggests that it may be under
selection by immune surveillance [41]. If so, B. pertussis
cells that express Tcf in vivo might be more rapidly cleared
by the immune system, and cells that do not express Tcf or
express a variant form, as a result of phase variation,
would have a selective advantage. However, through theBMC Genomics 2007, 8:122 http://www.biomedcentral.com/1471-2164/8/122
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continuous emergence of Tcf-expressing phase variants
within the population, production of this secreted viru-
lence factor could be maintained in temporal phases or
niches where the benefits of expressing it outweigh the
risk of increased susceptibility to immune clearance.
Frequent phase variation was also observed at the HPT in
the coding region of the bapC gene. By analogy to other B.
pertussis autotransporter family proteins that have been
implicated in pathogenesis, a role for this gene in viru-
lence has been proposed [46], but such a function has not
yet been demonstrated. Likewise, nothing is known about
the immune response to BapC, but its predicted localiza-
tion on the cell surface makes it a plausible target for
immune surveillance. In a previous study, partial sequenc-
ing of bapC from 10 B. pertussis strains identified only a
silent SNP [46], but the 5' end of the gene, which contains
the HPT, was not examined. Interestingly, bapC harbors a
second HPT (C14 in Tohama I), upstream of the HPT
assayed here, that may also be phase-variable (Table 1).
By characterizing fimX  allelic polymorphism and gene
expression, this study expands upon previous work on
phase variation of fimbrial major subunit genes. Among
the strains examined, seven were found to harbor a C8
HPT in the fimX promoter region, distinguishing them
from the majority of strains which carried a C7 tract. fimX
transcript abundance was found to be nearly fourfold
higher in C7 strains than in C8 strains, suggesting that this
single base difference may significantly influence tran-
scription, and arguing against the model in which fim-
brial gene expression is only activated when the distance
between the activator binding region and the -10 box
exceeds a threshold of 22 bases [26,27]. The data pre-
sented here suggest that the activity of these promoters
may be more subtly regulated by HPT expansions and
contractions, even when the tract is relatively short.
The C8 allele of the HPT in the fimX promoter was found
only in B. pertussis strains isolated prior to the introduc-
tion of pertussis vaccines, suggesting that vaccination may
have led to selection against strains carrying this allele.
Because the C8 HPT correlates with decreased fimX tran-
script levels, we propose that increased FimX expression
may confer a selective advantage in an immunized host
population. In B. pertussis populations from multiple
countries, initiation of a vaccination program using a
Fim2-expressing vaccine strain has led to the significant
enrichment of Fim3-expressing isolates (reviewed in [38].
By analogy, vaccine-induced selection against Fim2 may
have also led to the enrichment of strains that express
more FimX. Such a shift would not have been detected by
serotyping because only Fim2 and Fim3 antisera have
been used in these assays. The substitution of one fimbrial
subtype for another has been proposed as a mechanism to
evade the immune system without substantial loss of
adhesion [47].
Conclusion
Computational screening was used to identify signifi-
cantly long HPTs that were predicted to be prone to length
polymorphism in the genomes of three closely related
Bordetella species. A comparative genomic approach veri-
fied that many of these loci are, in fact, polymorphic
among the three species. In order to obtain evidence for
HPT length polymorphism within a single species, nine
HPT loci were genotyped using the PCR/LDR assay in a
collection of 90 B. pertussis strains. Polymorphism was
observed at six of these loci, suggesting that a thorough
examination of all 52 B. pertussis HPTs could reveal doz-
ens of previously unrecognized phase-variable genes.
Three HPTs displayed tract length polymorphism within
cultures derived from single colonies, indicating that they
are rapidly phase-variable. A fourth polymorphic HPT was
identified in the promoter of fimX where a single base
expansion variant was present only among strains that
were isolated prior to introduction of pertussis vaccines.
Transcript abundance of fimX was found to be 3.8-fold
lower in strains carrying the longer allele.
Given the diversity of alternate phenotypes that may be
generated by the 69 HPTs identified in this study, it is
likely that phase variation is involved in many aspects of
Bordetella pathogenesis. Because B. pertussis lacks genetic
diversity, phase variation may be a key mechanism for
adaptation to the hostile and changing host environment.
Future work to elucidate functional differences associated
with the phase variants described in this study may lead to
new insights into Bordetella host specificity, immune sys-
tem modulation, and niche adaptation.
Methods
Strains, media, and genomic DNA preparation
Strains used in this study are described in Additional file
6. Pre-vaccination era strains in the U.S. were defined as
strains isolated before 1949, when use of the whole-cell
pertussis vaccine became widespread [48]. U.S. strains iso-
lated subsequent to 1949 were considered to be post-vac-
cination era strains. Strains from the Netherlands were
considered pre-vaccination era strains if isolated prior to
1953, and post-vaccination era strains if isolated after
1953 [37]. Strains from Australia and Italy were not
included in the statistical analysis of fimX  polymor-
phisms, as pre- and post-vaccination status for each strain
was not available.
Single B. pertussis colonies from Bordet-Gengou agar (BD,
Franklin Lakes, New Jersey, United States) plates supple-
mented with 15% defibrinated sheep blood (BG blood
plates) were inoculated into modified Stainer-ScholteBMC Genomics 2007, 8:122 http://www.biomedcentral.com/1471-2164/8/122
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media (SS) and grown to stationary phase. Genomic DNA
was purified from bacterial cell pellets using the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI,
USA) as previously described [2].
Homopolymeric tract identification and statistical analysis
HPTs were identified by scanning Bordetella  genome
sequences (RefSeq NC_002927, NC_002928, and
NC_002929) using the equicktandem program of the
EMBOSS package [49]. Markov model transition proba-
bilities and observed number of HPTs were calculated
using calc_transition_matrices.pl and count_HPTs.pl
(available at [50]). For C or G HPTs, second through fifth
order Markov models yielded very similar observed/
expected curves, and for A or T HPTs, first and second
order Markov models yielded very similar observed/
expected curves, but higher order Markov models may
exhibit overfitting. Orthologous HPTs in the three Borde-
tella genomes were manually confirmed using ACT [51],
and alignments were verified using cross_match [52] and
ClustalW [53]. Routine statistical analyses were per-
formed using StatView v. 5.0.1 software (SAS Institute,
Cary, NC, USA).
The position of each intergenic HPTs was mapped relative
to adjacent genes in order to determine whether it could
influence transcriptional regulation. Because most Borde-
tella promoters have not been functionally characterized,
we made the assumption that the distribution of distances
between promoter and start codon would follow a similar
trend to the distribution found in the E. coli genome [54].
Extrapolating from this distribution, HPTs upstream of at
least one gene were considered highly likely to overlap a
promoter element when located between 21 and 80 nt
upstream of the start codon of an ORF. HPTs located fewer
than 21 nt, or between 81 and 150 nt upstream of the start
codon were considered to have a moderate likelihood of
overlapping a promoter, while those more than 150 nt
upstream were considered to have a low probability. HPTs
between adjacent, convergently transcribed ORFs were
assumed not to overlap a promoter.
PCR, cloning and sequencing
All PCR amplifications, unless otherwise indicated,
employed  Pfu  Ultra or Pfu  Turbo High Fidelity DNA
polymerase (Stratagene, La Jolla, CA, USA) according to
the manufacturer's instructions. Fidelity comparison
experiments used AmpliTaq DNA Polymerase (Ambion,
Austin, TX, USA). 25 μl reaction volumes contained 25 ng
of genomic DNA, 10 mM dNTPs, and 20 pmol of each oli-
gonucleotide primer (see Additional file 20 for PCR prim-
ers used). PCR parameters were 5 min at 96°C; followed
by 30 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 1
min; and a final 7 min extension step at 72°C. Reactions
were then heated for 30 minutes at 96°C to inactivate the
polymerase. 5 μl of the PCR reaction was visualized on a
2% agarose gel to confirm the presence of an amplifica-
tion product of the expected size. Selected PCR products
were sequenced directly (Elim Biopharmaceuticals, Hay-
ward, CA, USA) using one amplification primer. PCR oli-
gonucleotide primer (Integrated DNA Technologies,
Coralville, IA, USA) sequences are in Additional file 20.
Some PCR products were cloned as blunt-ended mole-
cules using the Zero Blunt TOPO PCR Cloning Kit and the
pCR II-Blunt TOPO vector (Invitrogen, Carlsbad, CA,
USA), according to the manufacturer's instructions, with
the following modifications to maximize efficiency when
cloning a pool of PCR products: 4 μl of PCR product, 1 μl
Salt Solution and 1 μl vector were incubated for 20 min-
utes; 4 μl of the cloning reaction was added to a vial of
One Shot Chemically Competent E. coli, which was then
gently mixed and incubated on ice for 5 minutes.
Colony PCR of B. pertussis strains was performed on pin-
prick size colonies grown on BG blood plates at 37°C by
resuspending a single colony in 10 μl of 1× Pfu Ultra High
Fidelity Polymerase Buffer (New England BioLabs,
Ipswitch, MA, USA), and incubating at 96°C for 10 min-
utes. The resulting cell lysate was centrifuged at 600 × g for
1 min. 2 μl of the cleared lysate was used as the genomic
template for subsequent PCR reactions as described
above.
LDR conditions
Uniplex PCR/LDR reactions contained 1 μl of a PCR reac-
tion, 25 nmol of labeled common oligonucleotide, and
25 nmol of one unlabeled discriminating oligonucle-
otide. Multiplex PCR/LDR reactions contained 1 μl of PCR
reaction mix, 25 nmol of labeled common oligonucle-
otide, and 25 nmol each of three different unlabeled dis-
criminating oligonucleotides. All LDR oligonucleotides
were synthesized and HPLC purified by Integrated DNA
Technologies (see Additional file 7). All PCR/LDR reac-
tions were performed in 1× Tth DNA Ligase Buffer (New
England BioLabs) at a final volume of 20 μl. The reaction
mixture was heated for 1.5 min at 94°C prior to adding 25
fmol of Tth  DNA Ligase (New England BioLabs). LDR
reactions were cycled 30 times, each cycle consisting of 15
s at 94°C and 2 min at 65°C. Reactions were stopped with
1.5 μl of 0.5 mM EDTA, then spiked with a custom mix-
ture of fluorescent 2',7'-dimethoxy-4',5'-dichloro-6-car-
boxyfluorescein (JOE)-labeled oligonucleotide molecular
weight standards (Integrated DNA Technologies) at 100
fmol. Reactions were analyzed using an ABI 3100 capil-
lary sequencing instrument (Applied Biosystems, Foster
City, CA, USA) at the Stanford Protein and Nucleic Acid
Biotechnology Facility (Stanford, CA, USA). In cases
where no ligation product was detectable, PCR products
were sequenced directly to determine HPT length.BMC Genomics 2007, 8:122 http://www.biomedcentral.com/1471-2164/8/122
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LDR data analysis
Raw trace data from ABI format output files were dis-
played as images using gel_draw.pl. Molecular weights of
ligation products were calculated from raw trace data by
comparing their mobility to that of oligonucleotide stand-
ards using ABImulti.py. Both of these scripts utilize the
convert_trace and scf_dump programs of the Staden pack-
age [55] for extraction of raw fluorescence intensity data
from ABI format output files. Software described in this
manuscript is available for download at [50].
Measurements of gene expression
Cultures of B. pertussis were established by inoculating a
single colony from a BG blood plate into 1.5 ml of SS,
incubating at 37°C with shaking until an OD600  of
approximately 2 was achieved, and sub-cultured, in dupli-
cate, to an OD600 of 0.05 in SS. These duplicate cultures
were then incubated at 37°C with shaking until aliquots
were harvested for RNA extraction during mid-log phase
(OD600 1.5 – 2.5). RNA was extracted and reverse tran-
scribed as previously described [56]. Quantitative RT-PCR
reactions were carried out in a final volume of 20 μl using
IQ Sybrgreen Supermix 2× Mix for Real-time PCR (Bio-
Rad Laboratories, Hercules, CA, USA), 1 μl cDNA (in RT
reaction mix), 1 μl DMSO, and 6 pmol each forward and
reverse primers (Integrated DNA Technologies; see Addi-
tional file 20). Real-time PCR was performed with an ABI
Prism 7900 HT sequence detection system (Applied Bio-
systems). Data were analyzed using the ΔΔCt method with
recA as the reference [57].
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